Ukraine International Airlines (UIA) has installed the first laboratory for PCR and antibody tests at Boryspil International Airport (Kyiv region).
UIA President Yevhen Dykhne said on Facebook that now the laboratory will be used to test UIA crews, however, it will also be able to provide for the needs of departing or arriving passengers, if the arrival country requires a corresponding certificate.
“For example, Tunisia, with which air traffic will soon be restored, allows free border crossing with the availability of a PCR test,” he added.
Dykhne said that a PCR test currently has the highest specificity and sensitivity, in contrast to rapid tests. The material for analysis is a throat swab, and the analysis takes three hours. At the same time, a possible simultaneous loading of the laboratory is 96 samples.
In addition, he said the laboratory also provides for the option of an urgent PCR test of one individual sample within 40 minutes and testing for antibodies to SARS-CoV-2, which allows to determine the earlier infection and the presence of immunity (the test material is blood from a vein, the speed is 86 tests per hour).
Darnitsa pharmaceutical company has suspended a project for the production of hydroxychloroquine for the treatment of COVID-19.
Аccording to the press service of the company, the company came to such a decision by tracking reputable medical studies regarding the effectiveness of hydroxychloroquine in the treatment of COVID-19. In particular, as of May 26, some 201 studies of the use of hydroxychloroquine for the treatment of COVID-19 were recorded, of which five were completed.
The company notes that the published clinical trial materials have not confirmed the benefits of using the experimental drug ‘hydroxychloroquine’ for patients with COVID-19.
“The safety of patients and scientific feasibility is an absolute priority for the company. Therefore, taking into account the world scientific thought, the company suspended the project for the production of hydroxychloroquine for the treatment of COVID-19,” Darnitsa said.
The company reminds that Darnitsa had launched the project to prepare for the production of hydroxychloroquine in March 2020, when Chinese treatment protocols and publications in authoritative sources about the effectiveness of this drug for the treatment of COVID-19 appeared. These data gave reason to include hydroxychloroquine in the protocols of experimental treatment of COVID-19 in many countries of the world, in particular in Ukraine, the United States and in European countries.
“At the same time, Darnitsa received numerous requests from Ukrainian doctors and patients asking for the opportunity to use the drug for treating coronavirus infection, since this therapy was considered by the medical community as potentially effective. Considering the scientific data and the medical community’s requests, Darnitsa started a project for the production of hydroxychloroquine preparations exclusively for the needs of medical institutions in the treatment of COVID-19,” the company’s press service said.
Darnitsa pharmaceutical company was founded in 1930. It is one of the ten largest pharmaceutical manufacturers in Ukraine and the top ten largest hospital suppliers. The strategic directions of the portfolio development are cardiology, neurology and solutions to pain problems.
The metro reopened in Kyiv and Kharkiv on May 25 after the two-month pause caused by coronavirus. In Kyiv, the metro service is back to the regular schedule. Passengers are required to wear masks, and there are signs indicating the obligatory 1.5-meter distance between passengers.
Metro workers are provided with personal protective equipment.
The Kharkiv metro reopened at 5:30 a.m. on Monday.
“Please be advised that it is prohibited to travel by the metro without a respirator or a mask,” the Kharkiv metro press service said on Facebook.
The metro service in Kyiv, Kharkiv, and Dnipro (former Dnipropetrovsk) had been unavailable since March 17 in order to contain the coronavirus outbreak.
The big privatization will be launched as soon as the coronavirus crisis is over, and the Dnipro Hotel will become its pilot project, President of Ukraine Volodymyr Zelensky has said.
“As to medium-sized and big privatization, everything is ready. It will be launched after COVID-19. The first target – the Dnipro Hotel – is ready. As we promised, we started with public administration agency,” he said at a press conference in Kyiv on Wednesday.
The president also said the rest of hotels on balance of the public administration agency will be handed over to the State Property Fund.
The privatization targets have been “cleared off” legal cases, Zelensky said.
PJSC Farmak pharmaceutical company (Kyiv) will use the German scientists’ protocol of clinical trials of the antiviral medicine efficiency, produced by Farmak for coronavirus (COVID-19) treatment, the company’s press service said with reference to Chairperson of the Supervisory Board of Farmak Filya Zhebrovska.
“This medicine was tested apart from human trials and showed good results. We need to come to clinical trials and conduct them, so that in the autumn we know that this medicine is effective and it can fight COVID-19. German scientists helped us indeed. They have prepared the clinical trial protocol correctly, so that we can investigate if this medicine is working according to all necessary criteria. This is a big, hard and expensive work,” she said.
Zhebrovska said that the antiviral medicine, which efficiency against COVID-19 Farmak plans to test, is also being studied by foreign research centers.
“There are good studies on our antiviral medicine at Oxford and Frankfurt universities,” she said.
Zhebrovska said that significant financial funds are needed for the development of COVID-19 vaccines, which Ukraine and the Ukrainian pharmaceutical companies do not currently have.
“The European Investment Bank organized a consortium together with the WHO and allocated EUR 7.6 billion for the development of vaccines for COVID-19. Neither Farmak, nor Ukraine, unfortunately, have such financial capacities. Perhaps we can join to these works at some stage,” she said.
Farmak is the leader in the pharmaceutical market of Ukraine in terms of sales. It exports products to 20 countries.
Ukrainian pharmaceutical company Microkhim (Rubizhne, Luhansk region) is ready to start production of a generic antiviral drug to combat the coronavirus disease (COVID-19) by the end of the year, Microkhim Director General Ihor Pohromsky has said in an interview with the Uriadovy Kurier government’s newspaper. “Now the key point is that we are transporting the substance. In the near future we will expose it to comprehensive analytical control, develop a dosage form and establish and conduct bioequivalence clinical trials. There is a lot of work ahead. There is a lot of professional work that we can do, but it has terms and limitations. However, the situation is such that, despite quarantine, we are ready to work to provide the country with a domestic drug this year, and I am sure that we will be first among national manufacturers, who will develop it,” he said, adding that it comes to the production of generic Avigan.
According to Pohromsky, “the drug was developed in Japan against several influenza viruses in 2014, and in 2015 it passed the third phase of clinical trials in the United States. It happened so that it was tested during an epidemic in Wuhan, and later allowed for experimental use in Italy against COVID-19. By the way, it has already become known that more than 30 countries have asked Japan to provide them with this drug for combating COVID-19. Japan has provided it to Ukraine to continue clinical trials involving patients with COVID-19.”
The general director said that the price of the generic drug made in Ukraine will be much lower than the price of the original. In addition, in the context of global hype, it is difficult to talk about the wholesale supply of original drugs to Ukraine. Therefore, according to Pohromsky, it is necessary to start domestic production.
